Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q2 2021 · 10-Q
Revenue$916.00K$916.00K+162.5% vs Q2 2020 Net Income-$595.00K-$595.00KN/M vs Q2 2020 EPS Diluted-$0.01-$0.01N/M vs Q2 2020 Gross Profit$553,000+167.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Operating Cash Flowderived-$209,000N/M Free Cash Flowderived-$539,000— Margins · derivedGross margin60.4%+1.1 pt vs Q2 2020
Operating margin-64.8%+125.1 pt vs Q2 2020
Net margin-65.0%+125.9 pt vs Q2 2020
ended Jan 31, 2021 · filed Mar 15, 2021 · 43 d after period end